In conclusion, our data suggest that HBV promotes sorafenib resistance in HCC by lowering SRSF2 and reducing ferroptosis via deregulation of PCLAF tv1 alternative splicing. This evidence concerns the gene SRSF2 and hepatocellular carcinoma.